MX2022002446A - Compuestos de pirrolopirimidina inhibidores de perk. - Google Patents

Compuestos de pirrolopirimidina inhibidores de perk.

Info

Publication number
MX2022002446A
MX2022002446A MX2022002446A MX2022002446A MX2022002446A MX 2022002446 A MX2022002446 A MX 2022002446A MX 2022002446 A MX2022002446 A MX 2022002446A MX 2022002446 A MX2022002446 A MX 2022002446A MX 2022002446 A MX2022002446 A MX 2022002446A
Authority
MX
Mexico
Prior art keywords
pyrrolopyrimidine compounds
perk inhibiting
perk
inhibiting
compounds
Prior art date
Application number
MX2022002446A
Other languages
English (en)
Inventor
Mark J Mulvihill
An- Hu LI
Matthew David Surman
Original Assignee
Hibercell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hibercell Inc filed Critical Hibercell Inc
Publication of MX2022002446A publication Critical patent/MX2022002446A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

Se proporcionan en la presente compuestos, composiciones y método útiles para inhibir PERK y tratar afecciones, enfermedades, y trastornos relacionados.
MX2022002446A 2019-08-29 2020-08-28 Compuestos de pirrolopirimidina inhibidores de perk. MX2022002446A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962893528P 2019-08-29 2019-08-29
PCT/US2020/048621 WO2021041975A1 (en) 2019-08-29 2020-08-28 Perk inhibiting pyrrolopyrimidine compounds

Publications (1)

Publication Number Publication Date
MX2022002446A true MX2022002446A (es) 2022-06-02

Family

ID=72470610

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002446A MX2022002446A (es) 2019-08-29 2020-08-28 Compuestos de pirrolopirimidina inhibidores de perk.

Country Status (11)

Country Link
US (1) US20220356186A1 (es)
EP (1) EP4021908A1 (es)
JP (1) JP2022546414A (es)
KR (1) KR20220066290A (es)
CN (1) CN114710956A (es)
AU (1) AU2020336975A1 (es)
BR (1) BR112022003584A2 (es)
CA (1) CA3152508A1 (es)
IL (1) IL290889A (es)
MX (1) MX2022002446A (es)
WO (1) WO2021041975A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022261352A1 (en) * 2021-06-09 2022-12-15 Icahn School Of Medicine At Mount Sinai Perfluoroalkane substituted pyrazolo[3,4-d]pyrimidin and pyrrolo[2,3-d]pyrimidin compounds and uses thereof
WO2023025912A1 (en) 2021-08-25 2023-03-02 Alesta Therapeutics BV Use of gcn2 inhibitors in treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903297A (en) 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
US7863444B2 (en) * 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
TR199902301T2 (xx) * 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
US9586967B2 (en) * 2013-11-08 2017-03-07 Ono Pharmaceutical Co., Ltd. Pyrrolo pyrimidine derivative
WO2016004254A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
GB201508747D0 (en) * 2015-05-21 2015-07-01 Univ Edinburgh Compounds
CN109153680B (zh) * 2016-07-07 2021-04-23 株式会社大熊制药 4-氨基吡唑并[3,4-d]嘧啶基氮杂双环衍生物及含其的药物组合物
EP4039675A1 (en) 2017-04-18 2022-08-10 Eli Lilly and Company Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds

Also Published As

Publication number Publication date
KR20220066290A (ko) 2022-05-24
JP2022546414A (ja) 2022-11-04
CN114710956A (zh) 2022-07-05
IL290889A (en) 2022-04-01
CA3152508A1 (en) 2021-03-04
AU2020336975A1 (en) 2022-03-31
EP4021908A1 (en) 2022-07-06
WO2021041975A1 (en) 2021-03-04
BR112022003584A2 (pt) 2022-05-24
US20220356186A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
JOP20210154B1 (ar) مثبطات kif18a
MX2023000410A (es) Analogos de rapamicina como inhibidores de mtor.
MX2023007581A (es) Analogos de rapamicina unidos a c26 como inhibidores de mtor.
EP4234031A3 (en) C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
MX2021007104A (es) Inhibidores de kif18a.
MX2022002877A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
PH12018501268A1 (en) Compounds useful as kinase inhibitors
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
PH12018501877A1 (en) Substituted indole mcl-1 inhibitors
MX2022001181A (es) Inhibidores de kif18a.
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
SG10201811384TA (en) Mnk inhibitors and methods related thereto
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
MX2021012423A (es) Métodos y composiciones para degradación de proteínas específicas.
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
CR20230362A (es) Inhibidores de cdk2 y métodos de uso de los mismos
WO2021011713A8 (en) Imidazopyrimidines as eed inhibitors and the use thereof
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MX2022002446A (es) Compuestos de pirrolopirimidina inhibidores de perk.
ZA202106519B (en) Caspase inhibitors and methods of use thereof
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
MX2022008627A (es) Pirazolo-pirimidinas sustituidas y usos de las mismas.